

# First 100 Days of the New Administration

## Overview

This panel discussed executive orders, agency directives, personnel moves, and expected policy changes in the first 100 days of the Trump Administration, as well as the implications for life sciences companies.

## Panel Questions

1. Thematically, how have the new Administration's topline objectives and implementation of them affected the way life sciences companies do business to date?
2. The Trump Administration began with a flurry of Executive Orders, many of which are now being challenged in court. What was behind the Administration's strategy and how do you think it is going to play out?
3. DOGE and Elon Musk are key players in the Trump Administration, especially when it comes to the composition and capabilities of departments and agencies. There is obviously much discussion about cutbacks in the federal workforce, but how should the private sector think about approaching their historical relationships with the government?
4. What do you think the most important effects will be from the Administration's work force reduction efforts?
5. What is the 10:1 Executive Order? How has it affected business so far?
6. The Trump Administration has signaled drug pricing remains a priority. What new policies do you anticipate?
7. Can you discuss the Trump Administration's position on IRA "negotiations"?

## Panel



**Krista Carver (Moderator)**

Partner, Washington  
+1 202 662 5197  
[kcarver@cov.com](mailto:kcarver@cov.com)



**Kristie Gurley**

Partner, Washington  
+1 202 662 5704  
[kgurley@cov.com](mailto:kgurley@cov.com)



**Jerry Masoudi**

Partner, Washington  
+1 202 662 5975  
[gmassoudi@cov.com](mailto:gmassoudi@cov.com)



**Matthew Schumaker**

Vice President, Head of Federal Government Affairs, Vertex Pharmaceuticals



**Nicholas Xenakis**

Of Counsel, Washington  
+1 202 662 5846  
[nxenakis@cov.com](mailto:nxenakis@cov.com)



# First 100 Days of the New Administration

8. What do you see as the potential future for the PDUFA user fee program? Will it look similar or different from PDUFA VII and its predecessors?
9. What key issues is FDA facing in the new Administration, and what do you expect its priorities to be?
10. While there is constant coverage of the White House and Trump, there are other branches of government. How do you expect with the Administration's relationship with Congress in particular to develop?
11. How has litigation against the Administration to challenge policies fared to date, and what are the practical implications for wins and losses?
12. How has the Loper Bright factored into the litigation and Trump HHS thus far?

## Additional Resources

- [Client Alert: Road Map to Trump Administration Drug Pricing Executive Order](#)
- [Client Alert: Executive Order: Directing the Repeal of Unlawful Regulations](#)
- [Client Alert: Executive Order on Deregulatory Initiative: What it Means for Food, Cosmetic, Drug, and Device Stakeholders](#)
- [Client Alert: Supreme Court Decides Major Administrative Law Cases; Implications for FDA-Regulated Companies](#)
- [Establishing the President's Make America Healthy Again Commission | The White House](#)

